Tarantino, P., Kim, S. E., Hughes, M. E., Patel, A., Smith, K., Brasó-Maristany, F., Paré, L., Davis, J., Mueller, C., Corgiat, B., Marín-Aguilera, M., Pardo, F., D'Amico, O., Martini, A., Kusmick, R. J., Tayob, N., Petricoin, E., Prat, A., Lin, N. U., Tolaney, S. M. (2025). Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1032